Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03866408CT.gov Insulin Regulation of Lipolysis and Lipolysis Proteins | — | Recruiting | — | — | — |
NCT03298464CT.gov Study of NGM313 in Obese Participants | — | Completed | — | — | — |
NCT02919176CT.gov Brown Fat Activation Study | — | Completed | — | — | — |
NCT01817400CT.gov Mediators of Abnormal Reproductive Function in Obesity (MARO) | — | Completed | — | — | — |
NCT02236962CT.gov Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment | — | Unknown | — | — | — |
NCT01748994CT.gov Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women | — | Completed | — | — | — |
NCT02305069CT.gov Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle | — | Completed | — | — | — |
NCT00855010CT.gov Pioglitazone on Pancreatic Steatosis and Bone Health | — | Completed | — | — | — |
NCT00843791CT.gov Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin | — | Terminated | — | — | — |
NCT00787644CT.gov Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma) | — | Terminated | — | — | — |
Show 5 more trialsShow fewer
NCT00775164CT.gov Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study | — | Withdrawn | — | — | — |
NCT00315146CT.gov Optimizing Body Composition for Function in Older Adults | — | Completed | — | — | — |
NCT00639457CT.gov Exercise and Pioglitazone for HIV-Metabolic Syndromes | — | Completed | — | — | — |
NCT00352287CT.gov Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults | — | Completed | — | — | — |
NCT00377975CT.gov "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pioglitazone (this asset) | Mayo Clinic | Approved | B · 63 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Pioglitazone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BBB · 79 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 75 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pioglitazone in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pioglitazone-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →